Dutch Femtech Startup YON E Health Raises 250K Euro

• The Dutch FemTech startup YON E Health has gained €250,000 in pre-seed funding
• This raised capital is expected to support the development of a smart vaginal health device that measures pH and temperature

Amsterdam-based Dutch FemTech startup YON E Health has closed a pre-seed funding round of €250,000 to develop an innovative smart vaginal health device that continuously measures pH and temperature, two key biomarkers linked to fertility, infection risk, and overall reproductive health.

It was led by PMK-Group, joined by UniPrisma Venture Studio, represented by Károly Szántó and Thijmen Meijer, who advised on term sheet development and negotiations. Matias Toye, founder of Oyster Shield and Dilicheck, gave M&A and fundraising support.

Founder and CEO Roswitha Verwer said the company was motivated to tackle taboos around vaginal health to underline its importance to innovation and investment.

This investment is a reflection of growing diversity in FemTech funding across Europe in 2025. Besides YON E Health, several startups in the women's health vertical have also raised sizeable rounds, including Hormona for hormone tracking (UK, €7.8 million), Solence for AI-based PCOS therapies (France, €1.6 million), SheMed for personalized healthcare (€43 million), and Unfabled for women's health retail solutions (€3 million).

YON E Health's product sits at the early stage of this growing market, combining clinical-grade biosensor technology with accessible at-home use.

The company's first device enables constant monitoring of vaginal pH and basal body temperature, offering real-time data that supports fertility tracking, infection prevention, and reproductive wellbeing.

Set up in 2022 by Verwer, YON E Health includes a global multidisciplinary team from Amsterdam, Budapest, London, Texas, Boston, and Madrid.

The goal of the company is to bridge gaps in women's health through proactive, data-driven tools that replace the reactive symptom-based approaches.

Dr. Muskaan Bhan, Chief Clinical Officer, focused on the fact that vaginal health is basic to a woman's overall well-being, and how the company's technology enables women with real-time clinical insight to prevent complications early.

Meanwhile, women's health remains underfunded; it commands less than 1 percent of global medical research funding and accounts for 2.3 percent of VC in 2024 to female-founded or women-focused ventures. This gap is to be bridged with innovation and scientific validation from YON E Health.

The pre-seed funding will go toward preparations for medical trials and the advancement of the device toward clinical and consumer use.

According to Dr. Peter M. Kovacs, “YON E Health is addressing a critical, yet underserved area in medicine. The integration of biosensor technology, clinical knowledge, and user-centered design is a meaningful step toward proactive women's healthcare."